AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company, on Friday said its Board has approved an amended stock repurchase plan allowing the company to buy back up to $100 million of its stock.
The repurchase plan runs through March 31, 2026.
The new authorization comes as an addition to the $6.4 million remaining under its existing $75 million program, under which the company has repurchased 3,443,188 shares, representing 11.2% of shares outstanding at the plan's start.
The company expects to end 2025 with about $300 million in cash, cash equivalents and investments.
A one-time $75 million commercial sales milestone is anticipated from GSK in the fourth quarter of 2025 once Jemperli reaches $1 billion in global net sales.
On Thursday, AnaptysBio closed trading 1.76% higher at $37.66 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.